Technology
Bukwang Pharmaceutical (003000.KS) reported Q3 2026 revenue of KRW 57.97 billion, up 21.2% year over year, and operating profit of KRW 2.16 billion, up 120.7%. However, nine-month operating profit fell 22.2% as research spending increased. Latuda's commercial growth and Contera Pharma's CP-012 Parkinson's disease program provide long-term opportunities, but sustained profitability remains unproven. Korea Alpha estimates fair value at KRW 3,700 per share, implying 4.3% downside from the October 22 closing price.
October 23, 2026 · 6 min